Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP)
R. C. Read, A. Torres, H. Lode, J. Carlet, J. H. Winter, J. Garau, T. Welte, M. A. Le Berre, J. E. Ambler, S. H. Choudhri, P. Arvis (Sheffield, Dundee, United Kingdom; Barcelona, Spain; Berlin, Hannover, Germany; Paris, Puteaux, France; West Haven, USA)
Source: Annual Congress 2006 - Community-acquired pneumonia: risk factors and treatment
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. C. Read, A. Torres, H. Lode, J. Carlet, J. H. Winter, J. Garau, T. Welte, M. A. Le Berre, J. E. Ambler, S. H. Choudhri, P. Arvis (Sheffield, Dundee, United Kingdom; Barcelona, Spain; Berlin, Hannover, Germany; Paris, Puteaux, France; West Haven, USA). Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP). Eur Respir J 2006; 28: Suppl. 50, 2083
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: